Skip to content

US · DXR · MEDICAL - INSTRUMENTS & SUPPLIES

Daxor Corporation (DXR) intrinsic value and stock valuation

$7.45as of 2026-11-21 · Mkt cap 61.18M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Daxor Corporation DCF and intrinsic value

InvestorsCraft values DXR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DXR’s statements →

Daxor Corporation Graham Number

Graham Number: $19.52d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Oak Ridge, TN 37830 daxor.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$500K
20112025
Net income
$9.17M
20112025
Free cash flow
-$-600K
20112025
Total equity
$45.9M+24% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$500K$2.13M$34.6M-$-350K-$-2.62M
Operating income$9.19M$620K$330K$5.25M$4.75M
Net income$9.17M$540K$280K$5.18M$4.75M
EPSd$1.84M$111.6K$60.5K$603.7K$1.18M
Operating cash flow-$-600K$30K-$-3.66M-$-770K-$-2.76M
Capital expenditure$0.00$0.00$0.00-$0.00-$0.00
Free cash flow-$-600K$30K-$-3.66M-$-770K-$-2.76M
Total assets$46M$36.6M$34.9M$30.3M$25M
Total debt$110K$730K$760K$1.23M$3.02M
Net debt$110K$730K$760K$1.23M$2.31M
Total equity$45.9M$35.8M$34M$29M$21.2M
Cash and short-term investments$0.00$0.00$0.00$0.00$710K
Income statement
20252024202320222021
Revenue$500K$2.13M$34.6M-$-350K-$-2.62M
Cost of revenue$310K$0.00$180K$1.09M$1M
Gross profit$190K$2.13M$34.4M-$-1.44M-$-3.62M
Research and development expenses$0.00$0.00$0.00-$0.00$0.00
Selling, general and administrative expenses$0.00$290K$310K$1.09M$990K
Other expenses-$-9M$1.3M$630K$0.00$80K
Operating expenses-$-9M$1.59M$940K$1.09M$1.07M
Cost and expenses-$-8.68M$1.59M$34.3M-$-5.6M-$-7.38M
Interest income$30K$0.00$0.00$0.00$0.00
Interest expense$20K$90K$50K$70K$20K
Depreciation and amortization$0.00$1.44M$510K$860K$750K
Ebitda$9.19M$2.06M$330K$6.11M$4.75M
Operating income$9.19M$620K$330K$5.25M$4.75M
Total other income/expenses, net-$-20K-$-90K-$-50K-$-70K-$-20K
Income before tax$9.17M$540K$280K$5.18M$4.75M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$9.17M$540K$280K$5.18M$4.75M
Weighted average shares outstanding$4.99M$4.84M$4.63M$8.58M$4.04M
Weighted average diluted shares outstanding$4.99M$4.84M$4.63M$8.58M$4.04M
Balance sheet
20252024202320222021
Cash and short-term investments$0.00$0.00$0.00$0.00$710K
Net receivables$0.00$10K$10K$20K$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$0.00$20K$30K$40K$760K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$46M$36.6M$34.8M$30.2M$24.2M
Total non-current assets$46M$36.6M$34.8M$30.2M$24.2M
Total assets$46M$36.6M$34.9M$30.3M$25M
Accounts payable$0.00$110K$100K$60K$90K
Short-term debt$0.00$0.00$0.00$0.00$720K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$120K$110K$100K$60K$810K
Long-term debt$110K$730K$760K$1.23M$3.02M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$120K$730K$760K$1.23M$3.02M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$120K$840K$860K$1.29M$3.83M
Common stock$60K$50K$50K$50K$50K
Retained earnings$34.8M$25.6M$25.1M$24.8M$19.6M
Accumulated other comprehensive income (loss)$34.8M$0.00$0.00$24.8M$19.6M
Total equity$45.9M$35.8M$34M$29M$21.2M
Total investments$46M$36.6M$34.8M$30.2M$24.2M
Total debt$110K$730K$760K$1.23M$3.02M
Net debt$110K$730K$760K$1.23M$2.31M
Cash flow statement
20252024202320222021
Net income$9.17M$540K$280K$5.18M$4.75M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$1.25M$630K$790K$730K
Change in working capital$20K$10K$50K-$-10K$220K
Accounts receivable$10K$0.00$0.00$10K-$0.00
Inventory$0.00$0.00$0.00$20K$0.00
Accounts payable$20K-$-10K$40K-$-20K$10K
Net cash provided by operating activities-$-600K$30K-$-3.66M-$-770K-$-2.76M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$1.18M$1.94M$2.75M$2.69M$70K
Common stock issued$160K$0.00$4.53M$1.85M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-570K-$-30K$3.66M$60K$2.85M
Net change in cash$0.00$0.00$0.00-$-710K$90K
Cash at end of period$0.00$0.00$0.00$0.00$710K
Operating cash flow-$-600K$30K-$-3.66M-$-770K-$-2.76M
Capital expenditure$0.00$0.00$0.00-$0.00-$0.00
Free cash flow-$-600K$30K-$-3.66M-$-770K-$-2.76M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Daxor Corporation

        Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.

        CEO
        Michael Richard Feldschuh
        Employees
        37
        Beta
        0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Daxor Corporation (DXR)?

        InvestorsCraft does not currently publish an intrinsic value for DXR. How the IC value is calculated.

        Is DXR undervalued?

        InvestorsCraft does not publish an undervaluation signal for DXR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.